COBOL is in the headlines again, and this time it is because of artificial intelligence (AI) – sparking conversations with tools emerging that claim t.

Cathie Wood’s ARK ETF published their daily trades for Wednesday, February 18th, 2026, revealing significant activity in the biotech and tech sectors. The largest transaction of the day was the ...

Abstract: This paper studies the control-oriented recursive identification of finite impulse response systems with binary-valued observations. Inspired by the Maximum Likelihood method, a novel ...

On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ: RXRX) has been “horrendous” and he does not like to recommend horrendous stocks. On the earnings ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

From electronic health records and blood tests to the stream of data from wearable devices, the amount of health information people generate is accelerating rapidly. Yet, many users struggle to ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. For its second quarter, Recursion earned $19.2 million in ...

Learn how to use pattern-matching features in your Java programs, including pattern matching with switch statements, when clauses, sealed classes, and a preview of primitive type pattern matching in ...

The de-risking event relates to the acquisition of the 50% interest in an ENPP1 inhibitor program (REV102) that it didn't own from Rallybio (NASDAQ: RLYB). REV102 is being developed to treat ...